Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2019

Share Based Compensation Option And Incentive Plan [Abstract]

Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity for the three months ended March 31, 2019 and 2018:

	Number of Options			Weighted- Average Exercise Price		Weighted-Average Contractual Life (In Years)
Outstanding at December 31, 2018		2,076,153		$	2.28		6.51
Granted		750,000			0.48
Expired		(48,737	)		1.08
Outstanding at March 31, 2019		2,777,416		$	1.81		7.34
Exercisable at March 31, 2019		1,593,224		$	2.70		5.78
Vested and Expected to Vest at March 31, 2019		2,777,416		$	1.81		7.34

Outstanding at December 31, 2017		1,893,003		$	2.49		5.40
Granted		275,500			0.57
Forfeited		(1,500	)		0.83
Outstanding at March 31, 2018		2,167,003		$	2.24		5.49
Exercisable at March 31, 2018		1,272,677		$	2.72		3.90
Vested and Expected to Vest at March 31, 2018		2,167,003		$	2.24		5.49

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

For the three months ended March 31, 2019 and 2018, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:

	2019		2018
Risk-Free Interest Rate		1.82 %		1.82 %
Expected Life		5.00 years		7.00 years
Expected Volatility		152 %		159 %
Expected Dividend Yield		0 %		0 %

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

The following is a summary of restricted stock activity for the three months ended March 31, 2019 and March 31, 2018:

	Number of Shares			Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Recognition Period
Nonvested Outstanding at December 31, 2018		1,822,132		$	0.59
Released/Vested		(7,957	)		1.52
Nonvested Outstanding at March 31, 2019		1,814,175		$	0.59		2.01
Nonvested Outstanding at December 31, 2017		103,000			1.52
Released/Vested		(37,190	)		1.52
Nonvested Outstanding at March 31, 2018		65,810		$	1.52		1.85

Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]

The total stock-based compensation expense for employees and non-employees is included in the accompanying Condensed Consolidated Statements of Operations and as follows:

	Three Months Ended March 31,
	2019		2018
Research and Development	$	64,539	$	57,078
General and Administrative		168,367		88,469
Total Stock-Based Compensation Expense	$	232,906	$	145,547